With anti-CD38 in multiple myeloma, a survival benefit too long to be significant?

被引：0
|
作者：
Cazabat, Romain
机构：
来源：
HEMATOLOGIE | 2024年 / 30卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：10
相关论文
共 50 条
  • [41] High response rates with IMiD retreatment post anti-CD38 exposure in patients with Multiple Myeloma
    Ntanasis-Stathopoulos, Ioannis
    Gavriatopoulou, Maria
    Malandrakis, Panagiotis
    Fotiou, Despina
    Migkou, Magdalini
    Kanellias, Nikolaos
    Eleutherakis-Papaiakovou, Evangelos
    Theodorakakou, Foteini
    Roussou, Maria
    Terpos, Evangelos
    Kastritis, Efstathios
    Dimopoulos, Meletios-Athanasios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S154 - S154
  • [42] The effects of anti-CD38 monoclonal antibody and anti-HI antibody on pretransfusion testing in a patient with multiple myeloma
    Zhe Zhu
    Kairui Hong
    Yefang Ke
    Annals of Hematology, 2023, 102 : 1961 - 1962
  • [43] The effects of anti-CD38 monoclonal antibody and anti-HI antibody on pretransfusion testing in a patient with multiple myeloma
    Zhu, Zhe
    Hong, Kairui
    Ke, Yefang
    ANNALS OF HEMATOLOGY, 2023, 102 (07) : 1961 - 1962
  • [44] Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma
    Lee, Hyun Tae
    Kim, Yujin
    Park, Ui Beom
    Jeong, Tae Jun
    Lee, Sang Hyung
    Heo, Yong-Seok
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2021, 536 : 26 - 31
  • [45] Selinexor containing regimens in patients with multiple myeloma (MM) previously treated with anti-CD38 monoclonal antibodies (αCD38 mAbs).
    Gasparetto, Cristina
    Lipe, Brea
    Tuchman, Sascha
    Bahlis, Nizar J.
    Sutherland, Heather J.
    Rossi, Adriana C.
    Lentzsch, Suzanne
    Baljevic, Muhamed
    Callander, Natalie Scott
    Venner, Christopher P.
    Sebag, Michael
    White, Darrell
    Kotb, Rami
    Chen, Christine
    Biran, Noa
    Madan, Sumit
    LeBlanc, Richard
    DeCastro, Andrew
    Schiller, Gary J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [46] Mechanism of Action of a New Anti-CD38 Antibody: Enhancing Myeloma Immunotherapy
    Malavasi, Fabio
    Faini, Angelo Corso
    CLINICAL CANCER RESEARCH, 2019, 25 (10) : 2946 - 2948
  • [47] Anti-CD38 autoantibodies and diabetes
    Raymondjean, M
    M S-MEDECINE SCIENCES, 1998, 14 (10): : 1132 - 1133
  • [48] Survival and drug treatment patterns in multiple myeloma patients exposed to an anti-CD38 monoclonal antibody, a proteasome inhibitor and an immunomodulatory imide drugs
    Hoveling, Liza
    de Jong, Hilda J.
    Penning-van Beest, Fernie J.
    Holthuis, Emily
    Smits, Elisabeth
    Dalhuisen, Sander
    Dinkla, Sip
    Herings, Ron M. C.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 313 - 314
  • [49] Anti-CD38 monoclonal antibody impairs CD34+mobilization and affects clonogenic potential in multiple myeloma patients
    Zappaterra, Arianna
    Civettini, Ivan
    Cafro, Anna Maria
    Pezzetti, Laura
    Pierini, Silvia
    Anghilieri, Michela
    Bellio, Laura
    Bertazzoni, Paola
    Grillo, Giovanni
    Minga, Periana
    Pioltelli, Maria L.
    Ravano, Emanuele
    Sassone, Marianna
    V. Vigano, Clara
    Volpato, Elisabetta B.
    Gambacorti-Passerini, Carlo
    Rossini, Silvano
    Cairoli, Roberto
    Crocchiolo, Roberto
    BLOOD TRANSFUSION, 2024, 22 (04) : 328 - 337
  • [50] SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma
    Kassem, Sahar
    Diallo, Bere K.
    El-Murr, Nizar
    Carrie, Nadege
    Tang, Alexandre
    Fournier, Alain
    Bonnevaux, Helene
    Nicolazzi, Celine
    Cuisinier, Marine
    Arnould, Isabelle
    Sidhu, Sukhvinder S.
    Corre, Jill
    Avet-Loiseau, Herve
    Teillaud, Jean-Luc
    van de Velde, Helgi
    Wiederschain, Dmitri
    Chiron, Marielle
    Martinet, Ludovic
    Virone-Oddos, Angela
    BLOOD, 2022, 139 (08) : 1160 - 1176
12345